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Protein misfolding is now recognized to be a central
feature of neurodegenerative diseases. Alzheimer disease
(AD), Parkinson disease (PD), amyotrophic lateral scle-
rosis (ALS), prion diseases, and the polyglutamine (poly-
gln) diseases all represent proteinopathies—diseases in
which a particular protein or set of proteins misfolds
and aggregates. In the past decade, mutations have been
identified in an increasing number of genes underlying
specific forms of neurodegeneration—for example, genes
encoding amyloid precursor protein (APP) and presen-
ilins 1 and 2 in AD, parkin and alpha-synuclein in PD,
Cu/Zn superoxide dismutase in ALS, tau in frontotem-
poral dementia, prion protein in Creutzfeldt-Jacob and
Gerstmann-Straussler diseases, and at least eight differ-
ent proteins in the polygln diseases (Hardy and Gwinn-
Hardy 1998; Price et al. 1998). Identification of these
mutations was a first step in understanding the disease
process; next, it will be necessary to explain how specific
changes in disease proteins may alter the neuron’s phys-
iology and to further question how neuronal responses
to the mutant protein influence the disease process. This
review examines the fate of mutant protein in neurons
and the potential role of posttranslational events in path-
ogenesis, with particular focus on the polygln diseases.
Posttranslational events have already been implicated
in various neurodegenerative diseases (Hardy and
Gwinn-Hardy 1998; Price et al. 1998). For instance,
mutations in familial AD—whether in APP or presenilins
1 or 2—influence the processing of amyloid precursor
protein, leading to increased production of amyloido-
genic forms of A-b peptide (Price et al. 1998). In fron-
totemporal dementia linked to chromosome 17, muta-
tions in the microtubule-associated protein tau reduce
its ability to bind to and promote the assembly of mi-
crotubules (Hong et al. 1998). In a recently identified
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hereditary form of PD, a mutation in the enzyme ubi-
quitin carboxy-terminal hydrolase L1 implicates the ubi-
quitin-proteasome–degradation pathway in pathogene-
sis (Leroy et al. 1998). Similarly, the amino-terminus of
parkin, the disease protein in another form of familial
parkinsonism, resembles ubiquitin, suggesting that the
molecular mechanism in this disease also involves pro-
tein-degradation pathways (Kitada et al. 1998). Several
posttranslational events may contribute to pathogenesis
in polygln diseases, including one or more listed in table
1. Some of these modifications of polygln proteins can
be observed in vitro or in cell culture, but evidence
from human disease tissue is still lacking (e.g., trans-
glutamination).
Polygln expansion is now recognized to be a major
cause of inherited neurodegenerative disease. To date,
eight polygln diseases have been identified (table 2). All
eight are caused by expansion of a CAG repeat that
encodes an abnormally long glutamine repeat in the oth-
erwise unrelated disease proteins. These progressive, ul-
timately fatal disorders typically begin in adulthood. The
diseases display distinct, yet overlapping, clinical and
pathological findings. However, in each disease the phe-
notype and severity can vary greatly, primarily because
of differences in repeat length. Longer repeats cause
more severe disease that begins earlier in life, sometimes
even in early childhood. With the very longest glutamine
repeats, the individual diseases seem to lose some of their
specific clinical and pathological features, becoming
characterized instead by a more extensive, less selective
pattern of neurodegeneration. Very long polygln expan-
sions may be so neurotoxic that they override their
specific disease context, causing a more widespread
“glutaminopathy.”
Polygln Protein Misfolding and Aggregation
The basis of these diseases is a dominant toxic gain
of function that occurs at the protein level and that in-
creases with longer glutamine repeats. The threshold for
disease (and the dominant toxic property) is a glutamine
repeat of ∼35–40 residues. As shown in table 1, there
are exceptions: the much shorter repeat in spinocere-
340 Am. J. Hum. Genet. 64:339–345, 1999
Table 1
Protein Fate in Polyglutamine Diseases: Potential Mediators/
Modulators of Pathogenesis
Posttranslational Event Component, Enzyme, or Pathway
Protein refolding/
disaggregation
Chaperone proteins
Degradation of misfolded
polypeptide
Ubiquitin-proteasome pathway
Cleavage of mutant
protein
Specific protease(s)
Altered nuclear transport Passive diffusion or active
transport
Crosslinking of mutant
protein
Transglutaminase
Altered binding to normal
substrates
Disease-specific interacting
proteins
bellar ataxia type 6 (SCA6) suggests, perhaps, a different
mechanism related to the calcium-channel properties of
the disease protein. In SCA3/Machado-Joseph disease
(SCA3/MJD), there is a gap between the largest normal
repeat (40) and the smallest expanded repeat (55), so
that an exact threshold cannot be determined. Evidence
increasingly suggests that the novel toxic property is mis-
folding of the polygln domain. Unique structural fea-
tures of polygln (Perutz et al. 1994) likely cause it to
adopt an altered conformation when it is expanded (per-
haps a b-sheet hairpin structure). Direct evidence for an
altered conformation is the existence of antibodies that
specifically bind expanded, but not normal, polyglutam-
ine (e.g., Trottier et al. 1995). A vast amount of indirect
evidence also suggests misfolding: numerous studies in
transfected cells and transgenic animals have shown that
expanded polygln forms insoluble aggregates, presum-
ably derived from misfolded protein (for example, Ikeda
et al. 1996; Paulson et al. 1997; Cooper et al. 1998,
Martindale et al. 1998; Merry et al. 1998). In vitro stud-
ies of recombinant huntingtin fragments have been
particularly informative. Scherzinger et al. (1997) de-
monstrated that huntingtin polygln aggregation is a self-
driven process that occurs in a concentration- and repeat
length–dependent manner and results in the formation
of amyloid-like insoluble fibrils. The threshold repeat
length for aggregation closely mirrors the threshold for
disease, supporting the view that polygln misfolding is
the dominant toxic property. It remains controversial
whether the aggregation that results from this misfolding
contributes to pathogenesis or is simply a by-product of
the disease process.
A major clue that protein misfolding actually occurs
in vivo was the discovery of neuronal intranuclear in-
clusions (NIs) containing the mutant protein (fig. 1).
These spherical, ubiquitinated aggregates have now been
described in all but two polygln diseases and in many
transgenic models (table 1) (see also Warrick et al. 1998;
Davies et al. 1997); intriguingly, the two exceptions,
SCA2 and SCA6, have the shortest glutamine repeats.
In addition, aggregates outside the nucleus have been
noted in HD (dystrophic neurites or neuropil aggre-
gates), and increased perinuclear staining for ataxin-2
in SCA2 may represent aggregated material (Huynh et
al. 1999).
The discovery of NIs was exciting because they seemed
to represent a unifying pathological structure found pri-
marily in the neurons most susceptible to degeneration.
This fact suggested that NI formation might be impor-
tant both to pathogenesis and to the selective vulnera-
bility seen in each disease. On the basis of recent findings,
however, the link between NIs and neuronal suscepti-
bility now seems less compelling. For example, certain
striatal neurons are among the most vulnerable neurons
in HD but reportedly do not develop abundant NIs (C.-
A. Gutekunst and S. Hersch, personal communication).
Mouse models of disease also suggest a dissociation be-
tween NIs and degeneration: transgenic mice expressing
a fragment of mutant huntingtin have massive numbers
of NIs, with relatively little neurodegeneration (Davies
et al. 1997), whereas mice expressing full-length mutant
huntingtin undergo significant striatal degeneration
without many NIs (Reddy et al. 1998). An in vitro neu-
ronal model of HD also failed to show a correlation
between neuronal death and NI formation, suggesting
that NIs may be irrelevant or even beneficial (Saudou et
al. 1998). Most importantly, recent results in the study
of SCA1 transgenic mice strongly suggest that visible
nuclear aggregates are not required for the initiation of
pathogenesis (Klement et al. 1998).
These findings notwithstanding, it is still too early to
conclude that NIs have no role in pathogenesis. The slow
progression of polygln disease in humans, together with
results from transgenic mouse models, suggest a multi-
step model of pathogenesis characterized by at least two
phases, an early and prolonged period of neuronal dys-
function and a later period of neuronal demise. If NIs
do play a role in pathogenesis, it is likely to be late, near
the point of neuronal demise. One way that NIs might
compromise neuronal function is by sequestering tran-
scription factors or other regulatory nuclear proteins.
Many transcription factors contain glutamine-rich or
pure polygln domains, and recent studies of transfected
cells, transgenic flies, and human tissue all indicate that
NIs can sequester certain other polygln-containing pro-
teins, such as the basal transcription-factor TATA-bind-
ing protein (Perez et al. 1998).
Importance of Nuclear Localization
Although the role of NIs remains uncertain, nuclear
expression of polygln proteins is clearly implicated in
pathogenesis. In SCA1 transgenic mice, neuronal degen-
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Table 2
Polyglutamine Diseases
Diseasea Protein
Repeat Length
in Disease Evidence for Aggregation
HD Huntingtin 38–180 NI, dystrophic neurites
DRPLA Atrophin 49–88 NI
SBMA Androgen receptor 38–65 NI
SCA1 Ataxin-1 39–83 NI
SCA2 Ataxin-2 34–59 Dense cytoplasmic staining (?)
SCA3/MJD Ataxin-3 55–84 NI
SCA6 Calcium channel 21–30 ?
SCA7 Ataxin-7 34–1200 NI
NOTE.—References for aggregation in disease tissue are the following: DiFiglia et
al. (1997); Paulson et al. (1997); Becher et al. (1998); Holmberg et al. (1998); Li et
al. (1998); Huynh et al. (1999).
a DRPLA  dentatorubral-pallidoluysian atrophy; SBMA  spinobulbar muscular
atrophy.
eration does not occur when mutant ataxin-1 is targeted
to the cytoplasm instead of to its normal nuclear location
(Klement et al. 1998). Also, in transfected neurons, mu-
tant huntingtin induces apoptosis only when the protein
is localized to the nucleus (Saudou et al. 1998). Several
studies further suggest that, compared with the cyto-
plasm, the nuclear environment favors aggregation (Kle-
ment et al. 1998; Perez et al. 1998), perhaps because the
nucleus is less efficient than the cytoplasm at degrading,
refolding, or disaggregating misfolded protein. Alter-
natively, the intricate structure of the nucleus might con-
centrate mutant proteins in subdomains that foster
aggregation. Whatever the mechanism, one wonders
whether there is a connection between the aggregation-
promoting property of the nucleus and its being the site
of toxicity. Ways that mutant protein, either as misfolded
monomers or as aggregates, might alter vital nuclear
functions are easy to imagine. The existence of gluta-
mine-rich transcription factors suggests that mutant pro-
tein might bind such factors inappropriately, altering
transcription of genes that are critical for neuronal func-
tion; other nuclear functions, such as mRNA splicing or
the export of proteins and RNA to the cytoplasm, could
be disrupted in a similar manner. Altered mRNA pro-
cessing is a particularly intriguing hypothesis, because it
has been suggested to underlie degeneration in the
motor-neuron diseases, ALS and spinal muscular atro-
phy (Lin et al. 1998; Pellizzoni et al. 1998) and because
at least two polygln disease proteins (ataxin-2 and atro-
phin) contain motifs found in RNA-splicing proteins.
The importance of nuclear localization raises its own
set of questions. First, in diseases such as SCA2, in which
the protein is apparently cytoplasmic and NIs have not
been observed, will the nucleus still be a primary site of
pathogenesis? Second, do NIs preferentially form within
particular subnuclear domains, such as promyelocytic
leukemia protein (PML) nuclear bodies (Hodges et al.
1998), and, if so, does this disrupt nuclear function in
predictable ways? Third, how does a large cytoplasmic
protein like huntingtin accumulate in the nucleus, and
why does this happen only in the disease state? A rel-
atively small polygln protein like ataxin-3 may be able
to enter the nucleus by passive diffusion, but transport
of full-length huntingtin and other large polygln proteins
would require karyopherin-mediated transit through the
nuclear pore. Data from cellular and transgenic models
are most consistent with a fragment of huntingtin en-
tering the nucleus (Cooper et al. 1998; Martindale et al.
1998). Whether this fragment is preferentially generated
from mutant huntingtin remains to be seen.
Proteases and Chaperones in Polygln Disease
In AD, the role of proteolytic processing in patho-
genesis is widely accepted. In polygln diseases, such a
role for proteolysis is also much anticipated but has not
yet been established. Several converging lines of evidence
make the proteolysis model compelling. First, immu-
nohistochemical studies of at least three diseases indicate
that polygln-containing fragments, not the full-length
protein, are the constituents of NIs (ataxin-1 inclusions
in SCA1 may be an exception). Second, proteolytic frag-
ments of disease protein have been reported in the HD
brain (DiFiglia et al. 1997) and in cell-based models of
several diseases; in some of these cellular models, pro-
teolytic fragments are preferentially seen with expanded
polygln protein (Goldberg et al. 1996; Merry et al.
1998). Third, studies of recombinant protein and trans-
fected cells have shown that many disease proteins are
substrates for caspases (Goldberg et al. 1996; Wellington
et al. 1998). Finally, polygln-containing fragments that
have been freed from their surrounding protein context
are particularly potent pathogenic molecules that are
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Figure 1 NIs in SCA3/MJD contain the proteasome. Pontine neurons from disease brain contain NIs (arrows) that immunohistochemically
stain for ubiquitin (left), the 20S proteasome core (middle), and the 19S cap of the proteasome complex (right) (immunostaining for the disease
protein, ataxin-3, is not shown). The arrowhead (right) indicates a nucleolus. Sections were not counterstained.
more prone than full-length protein to misfold, aggre-
gate and cause cell death in cell-based and transgenic
models (Ikeda et al. 1996; Paulson et al. 1997; Martin-
dale et al. 1998; Merry et al. 1998). Although this last
point does not constitute evidence for proteolysis, it sug-
gests how proteolysis might accelerate the disease pro-
cess. However, well-characterized, disease-specific pro-
teolytic fragments are still lacking. Moreover, evidence
in SCA1 suggests that pathogenesis and aggregation may
occur via the full-length protein in this disease. Definitive
answers will most likely come from transgenic models,
in which potentially relevant proteolytic fragments
should be easier to characterize.
Cells have a complex array of chaperone proteins that
assist in the folding, refolding, and elimination of pro-
teins under both normal and stress conditions such as
heat shock. If the central problem in polygln disease is
protein misfolding, then the cell might be expected to
mount a chaperone stress response that assists in the
refolding, elimination, and/or disaggregation of ex-
panded polygln protein. Studies of at least two diseases,
SCA1 and SCA3/MJD, suggest that this may indeed be
the case. In disease tissue and in transfected cells, specific
cellular chaperones are redistributed into NIs and poly-
gln aggregates, most notably heat-shock protein (Hsp)
40 family members (Bailey et al. 1998; Cummings et al.
1998; Paulson et al. 1998). In certain transfected cell
lines, polygln aggregates also cause an upregulation of
Hsp70 that colocalizes to the aggregates; however, neu-
rons from the SCA3/MJD brain only rarely show in-
duced Hsp70. Hence, if this response occurs in human
disease, it must take place near the point of neuronal
death (Paulson et al. 1998; author’s unpublished data).
The simplest interpretation of chaperonin redistribution
is that it is an appropriate cellular response to handle
misfolded and aggregated polypeptides. It is possible,
however, that this redistribution into aggregates could
titrate out chaperonins that otherwise would serve nor-
mal chaperoning functions in the neuron. Importantly,
overexpression of the Hsp40 protein, human DnaJ hom-
olog HDJ-2/HSDJ, can reduce the aggregation of polygln
proteins (Cummings et al.1998; Paulson et al. 1998).
This ability to reduce aggregation by overexpressing
chaperonins now allows researchers to test directly
whether modulating aggregation has a beneficial or del-
eterious effect. A fly model of polygln disease (Warrick
et al. 1998) that recapitulates many cellular features of
polygln disease, including NI formation and late-onset
degeneration, will be particularly useful for such
experiments.
Another major intracellular pathway for the recog-
nition and handling of abnormal protein is the ubiquitin-
proteasome pathway, which is also implicated in polygln
disease. The proteasome complex is responsible for the
ubiquitin-dependent degradation of most cytosolic pro-
teins, including misfolded or damaged proteins. Protea-
somes are abundant in neurons, where precisely con-
trolled protein degradation is probably required to
maintain neuronal function. Several recent studies have
shown redistribution of the proteasome complex into
NIs (Bailey et al. 1998; Cummings et al. 1998; Paulson
et al. 1998). As shown in figure 1, the two major com-
ponents of the proteasome complex, the 20S proteolytic
core and the 19S regulatory cap, both redistribute into
NIs in SCA3/MJD. It is unclear whether proteasomal
redistribution in polygln disease benefits or harms neu-
rons. A working model is that the proteasome represents
a first-line cellular defense that recognizes and eliminates
misfolded polygln protein before it aggregates. This
model of proteasome action is supported by studies
showing that proteasome inhibitors promote aggrega-
tion of moderately expanded polygln repeats, possibly
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by increasing the intracellular concentration of mis-
folded monomers (Chai et al., in press). If proteasome
redistribution into NIs effectively depletes the neuron of
functioning proteasomes, the result would be deleterious
to the cell: fewer active proteasomes to degrade abnor-
mal protein, which would lead to a further increase in
misfolded polygln protein. It will be important to de-
termine, by means of reconstitution experiments, how
well the proteasome degrades expanded polygln protein.
To be degraded by the proteasome, a protein must first
be unfolded, to enter the central proteolytic chamber of
the 20S core. Expanded polygln may adopt an energet-
ically stable structure that resists unfolding and thus
blocks entrance to the chamber or that causes incomplete
degradation of the polypeptide.
Disease Progression and Selective Vulnerability:
Relationship to Misfolding
Two fundamental characteristics of neurodegenerative
proteinopathies are the delay in onset and the selective
vulnerability. Polygln diseases are no exception to this
general rule. Signs of disease typically do not begin until
adulthood, despite expression of the mutant protein
throughout life. This delay suggests either an accumu-
lation of a toxic product (possibly protein aggregates)
or cumulative damage to one or more critical cellular
processes, such as mitochondrial oxidative phosphory-
lation (Knight et al. 1999 [in this issue]), axonal trans-
port, subnuclear organization, or proteasome function.
In either case, the toxic product or cumulative damage
likely reaches a threshold level beyond which the neuron
can no longer fully compensate.
Despite widespread expression of the various disease
proteins, certain populations of neurons are particularly
susceptible to degeneration, and the basis of this vul-
nerability remains a crucial question. Selective vulner-
ability is not absolute but, rather, represents a continuum
of susceptibility in different neuronal populations. For
instance, in the most severe early-onset cases due to the
longest repeats, degeneration is rather widespread,
and, even in typical adult-onset cases, the pathological
changes in advanced disease extend beyond the neuronal
populations that are known to be most susceptible.
Factors contributing to selective vulnerability can be
grouped broadly into two categories: those that increase
the level of misfolded protein or directly promote mis-
folding, and those that act downstream of misfolding.
The expression level of the disease protein clearly falls
into the first category. Although the various disease pro-
teins are widely expressed in the brain, absolute ex-
pression levels in different neurons certainly will vary,
which will contribute to the differences in intracellular
concentration of misfolded monomer. Some of the post-
translational modifications discussed here also would
fall under the first category. In susceptible neurons, for
example, misfolding and aggregation could be promoted
by specific proteolytic events that release a polygln frag-
ment or by aberrant targeting of polygln protein to the
nucleus. In addition, specific interacting proteins are
likely to contribute to selective vulnerability through
both categories. For instance, certain interacting proteins
may bind to disease proteins in a way that promotes
misfolding and aggregation, as was recently demon-
strated for the huntingtin interacting protein, SH3-con-
taining Grb2-like protein (SH3GL3) (Sittler et al. 1998).
Other specific interacting proteins are likely to influence
events downstream of misfolding, through mechanisms
that are linked to the specific functions of the disease
proteins. For example, in each disease, a subset of spe-
cific interacting proteins may bind more or less avidly
to the mutant protein, thereby altering physiological or
biochemical properties of one or both proteins. The sus-
ceptibility of a neuron to the downstream effects of the
mutant protein would depend, in part, on the particular
interacting proteins it expresses. The ataxin-1 interacting
protein LANP (cerebellar leucine-rich acidic nuclear pro-
tein) is just one of a number of recently identified in-
teracting proteins that may contribute in this manner to
selective vulnerability (Matilla et al. 1997).
The recent profusion of mammalian and invertebrate
transgenic models of polygln disease will aid consider-
ably in defining cellular pathways and proteins that me-
diate or modulate pathogenesis. In particular, genetic
screens in Drosophila models should prove especially
useful in identifying modifiers of misfolding and degen-
eration (Jackson 1998; Warrick et al. 1998). As modi-
fiers are identified, we can expect that some will tie into
one or more of the cellular pathways described here,
thus leading the way toward novel therapies for these
fatal diseases.
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